Ankylosing spondylitis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• IL-17 2
• TNF 2
• JAK 1
• IL-23 1
• NLRP3 0
• STAT3 0
• TLR4 0
• COX-2 0
• IL-6 0
• MAPK 0
• NRF2 0
• PD-1 0
• AKT 0
• AXL 0
• BDNF 0
• CD40 0
• CGRP 0
• CXCR4 0
• ERK 0
• FAK 0
• G6PD 0
• HIF-1 0
• IL-1 0
• IL-15 0
• MEK 0
• NF1 0
• PD-L1 0
• PI3K 0
• PIK3CA 0
• PPAR 0
• RANKL 0
• VEGF 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 712 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Hematological Parameters in Axial Spondyloarthritis

  NCT05450133· Bozyaka Training and Research Hospital· Updated 1 May 2025

  “primary researcher is not avaible to recruit participants”Registry text, quoted unchanged. Source

• Terminated

  A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil

  NCT06715254· Novartis Pharmaceuticals· Updated 4 Dec 2024

  “Due to the limited availability of eligible patients who met the study's criteria, as well as there has not been a case of tuberculosis, the study was terminated early.”Registry text, quoted unchanged. Source

• Withdrawn

  Terbinafine Treatment of Axial Spondyloarthropathy

  NCT05119712· Oregon Health and Science University· Updated 28 Aug 2023

  “Study stopped due to poor recruitment.”Registry text, quoted unchanged. Source

• Withdrawn

  Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy

  NCT04483687· Gilead Sciences· Updated 11 Jan 2021

  “Development program terminated”Registry text, quoted unchanged. Source

• Withdrawn

  Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy

  NCT04483700· Gilead Sciences· Updated 11 Jan 2021

  “Development program terminated”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment

  NCT04638647· Novartis Pharma AG· Source

• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

  NCT04436640· UCB Biopharma SRL· Source

• Inspiratory Muscle Training in Axial Spondyloarthritis

  NCT07914439· Bursa Yuksek Ihtisas Training and Research Hospital· Source

• A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

  NCT07133633· Merck Sharp & Dohme LLC· Source

• An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

  NCT06668181· UCB Biopharma SRL· Source

• Nurse-Led Exercise Program for Older Adults With Ankylosing Spondylitis

  NCT07891507· Mansoura University· Source

• A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

  NCT05622708· Novartis Pharmaceuticals· Source

• Taekwondo for Axial Spondyloarthritis

  NCT06823726· Wonju Severance Christian Hospital· Source

• Optimizing treatment strategy in axial spondyloarthritis by molecular imaging with Technetium-labeled certolizumab pegol.

  2023-505694-32-00· Universitair Ziekenhuis Gent· Source

• A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

  NCT04527380· Eli Lilly and Company· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Mendelian Randomization Analysis 19
• Gene Expression Profiling 12
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 9
• Metabolomics 5
• Flow Cytometry 3
• Magnetic Resonance Imaging 71
• Machine Learning 10
• Deep Learning 8
• Cohort Studies 24
• Genome-Wide Association Study 23

• Diagnostic Accuracy of Flow Cytometric Detection of HLA-B27 Using ABCm3 Antibody Compared with that of PCR-SSP in Suspected Ankylosing Spondylitis.

  J Coll Physicians Surg Pak, May 2026

• The inhibition of miR-125b-5P prevented Treg differentiation through activating STAT3/HIF-1α pathway in PBMCs of ankylosing spondylitis.

  Arthritis Res Ther, Feb 2026

• Adalimumab-Induced Changes in NK Cells Phenotype, Receptors, and Functions After Clinical Remission of Behçet's Uveitis.

  Am J Ophthalmol, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.